Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress
Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress
默沙东宣布将在2024年联合欧洲胃肠病学周大会上展示Tulisokibart(Mk-7240)在溃疡性结肠炎和克罗恩病中的长期疗效和安全性数据。
Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress
默沙东宣布将在2024年联合欧洲胃肠病学周大会上展示Tulisokibart(Mk-7240)在溃疡性结肠炎和克罗恩病中的长期疗效和安全性数据。
资讯热榜
更新时间